Literature DB >> 29782572

Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer.

Jyoti Malhotra1, Salma K Jabbour1.   

Abstract

Entities:  

Year:  2018        PMID： 29782572      PMCID： PMC5943224          DOI： 10.21037/tlcr.2018.03.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

1.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

Authors:  K Kelly; J Crowley; P A Bunn; C A Presant; P K Grevstad; C M Moinpour; S D Ramsey; A J Wozniak; G R Weiss; D F Moore; V K Israel; R B Livingston; D R Gandara
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

Review 2.  Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Paul G Kluetz; Diana T Chingos; Ethan M Basch; Sandra A Mitchell
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

3.  Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.

Authors:  Julie R Brahmer; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Jin Zhang; Gregory M Lubiniecki; Anne C Deitz; Reshma Rangwala; Martin Reck
Journal:  Lancet Oncol       Date:  2017-11-09       Impact factor: 41.316

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

5.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

Review 7.  Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.

Authors:  Joachim G Aerts; Joost P Hegmans
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

8.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Authors:  Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

9.  Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis.

Authors:  Johnathan Man; Georgia Ritchie; Matthew Links; Sally Lord; Chee Khoon Lee
Journal:  Asia Pac J Clin Oncol       Date:  2018-01-19       Impact factor: 2.601

10.  Health-related quality of life results from the phase III CheckMate 067 study.

Authors:  Dirk Schadendorf; James Larkin; Jedd Wolchok; F Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher Lao; John Wagstaff; Margaret K Callahan; Michael A Postow; Michael Smylie; Pier Francesco Ferrucci; Reinhard Dummer; Andrew Hill; Fiona Taylor; Javier Sabater; Dana Walker; Srividya Kotapati; Amy Abernethy; Georgina V Long
Journal:  Eur J Cancer       Date:  2017-06-23       Impact factor: 9.162
View more
  1 in total

1.  Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.

Authors:  Julia Ruark; Erin Mullane; Nancy Cleary; Ana Cordeiro; Evandro D Bezerra; Vicky Wu; Jenna Voutsinas; Bronwen E Shaw; Kathryn E Flynn; Stephanie J Lee; Cameron J Turtle; David G Maloney; Jesse R Fann; Merav Bar
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-09       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.